Policy & Regulation
llumina Appoints Dr. Phil Febbo as CMO
13 March 2018 - - San Diego, California-based DNA sequencing and array-based technologies specialist Illumina, Inc. (NASDAQ: ILMN) has named Dr. Phil Febbo as chief medical officer, effective March 26, 2018, the company said.
In his new role, Febbo will be responsible for developing and executing on the company's medical strategy to drive genomic testing into healthcare practice.
Febbo most recently served as CMO of Genomic Health (NASDAQ: GHDX). Prior to joining Genomic Health, he served as Professor of Medicine and Urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology.
Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital.
After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute).
Illumina serves customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.